Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.113278 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Christophe Le Tourneau und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Development and Innovation (D3i), Institut Curie, INSERM U900 Research Unit, Paris-Saclay University, Paris, France. Hauptthemen laut MEDLINE: Medical Oncology, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche, F. Hoffmann-La Roche Ltd.
Abstract (Originalsprache)
Personalised oncology, whereby patients are given therapies based on their molecular tumour profile, is rapidly becoming an essential part of optimal clinical care, at least partly facilitated by recent advances in next-generation sequencing-based technology using liquid- and tissue-based biopsies. Consequently, clinical trials have shifted in approach, from traditional studies evaluating cytotoxic chemotherapy in largely histology-based populations to modified, biomarker-driven studies (e.g. basket, umbrella, platform) of molecularly guided therapies and cancer immunotherapies in selected patient subsets. Such modified study designs may assess, within the same trial structure, multiple cancer types and treatments, and should incorporate a multistakeholder perspective. This is key to generating complementary, fit-for-purpose and timely evidence for molecularly guided therapies that can be used as proof-of-concept to inform further study designs, lead to approval by regulatory authorities and be used as confirmation of clinical benefit for health technology assessment bodies. In general, the future of cancer clinical trials requires a framework for the application of innovative technologies and dynamic design methodologies, in order to efficiently transform scientific discoveries into clinical utility. Next-generation, modified studies that involve the joint efforts of all key stakeholders will offer individualised strategies that ultimately contribute to globalised knowledge and collective learning. In this review, we outline the background and purpose of such modified study designs and detail key aspects from a multistakeholder perspective. We also provide methodological considerations for designing the studies and highlight how insights from already-ongoing studies may address current challenges and opportunities in the era of personalised oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Development and Innovation (D3i), Institut Curie, INSERM U900 Research Unit, Paris-Saclay University, Paris, France.
- Institut Gustave Roussy, Paris, France.
- Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
- Missie Tumor Onbekend, Amsterdam, Netherlands.
- Norwegian Medicines Agency, Oslo, Norway.
Förderung
- F. Hoffmann-La Roche
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Le Tourneau, C., André, F., Helland, Å., Mileshkin, L., Minnaard, W., Schiel, A., Taskén, K., Thomas, D. M., Veronese, M. L., Durán-Pacheco, G., Leyens, L., Rufibach, K., Thomas, M., & Krämer, A. (2023). Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113278
Vancouver
Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, et al. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.113278
BibTeX
@article{LeTourneau2023,
author = {Le Tourneau, Christophe and André, Fabrice and Helland, Åslaug and Mileshkin, Linda and Minnaard, Warnyta and Schiel, Anja and Taskén, Kjetil and Thomas, David M and Veronese, Maria Luisa and Durán-Pacheco, Gonzalo and Leyens, Lada and Rufibach, Kaspar and Thomas, Marlene and Krämer, Alwin},
title = {Modified study designs to expand treatment options in personalised oncology: a multistakeholder view},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.113278}
}
EUVIMED